# Neuronetics Inc. (STIM)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $86M  
**Price:** $1.31 (+5.65%)

> Neuronetics Inc. is a commercial stage medical technology and healthcare company focused on designing, developing, and marketing products that improve the quality of life for patients suffering from neurohealth and psychiatric disorders. Its primary offering is the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment delivered in office-based settings. This system generates pulsed, MRI-strength magnetic fields to stimulate specific brain areas associated with mood, serving as a therapeutic alternative for adults and adolescents aged 15-21 with major depressive disorder (MDD) when medications prove inadequate. Neuronetics Inc. operates a vertically integrated model that includes manufacturing and selling NeuroStar systems and treatment sessions, alongside owning and managing Greenbrook TMS Inc. treatment centers across the United States. These centers provide NeuroStar Advanced Therapy, along with other modalities like SPRAVATO for MDD and related conditions. The company engages with health policy stakeholders and payors to support coverage and reimbursement for TMS therapies, positioning itself as a leader in evidence-based, device-driven mental health solutions. Founded in 1998 and headquartered in Malvern, Pennsylvania, Neuronetics Inc. emphasizes expanding access to advanced neurohealth treatments through its direct sales, customer support, and clinical outcomes registry.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $149M | $72M | -$31M | -$39M | — |
| 2024 | $75M | $54M | -$35M | -$44M | — |
| 2023 | $71M | $52M | -$31M | -$30M | — |
| 2022 | $65M | $50M | -$35M | -$37M | — |
| 2021 | $55M | $44M | -$28M | -$31M | — |
| 2020 | $49M | $38M | -$22M | -$27M | — |
| 2019 | $63M | $47M | -$27M | -$29M | — |
| 2018 | $53M | $40M | -$20M | -$24M | — |
| 2017 | $40M | $31M | -$14M | -$16M | — |
| 2016 | $34M | $28M | -$9M | -$11M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $142M | $115M | $22M | $28M | $66M |
| 2024 | $141M | $109M | $28M | $18M | $55M |
| 2023 | $116M | $82M | $34M | $60M | $59M |
| 2022 | $117M | $60M | $57M | $70M | $36M |
| 2021 | $141M | $56M | $85M | $94M | $35M |
| 2020 | $79M | $53M | $25M | $49M | $35M |
| 2019 | $100M | $52M | $48M | $76M | $31M |
| 2018 | $117M | $46M | $71M | $105M | $30M |
| 2017 | $39M | $44M | -$193M | $29M | $30M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$20M | — | — |
| 2024 | -$31M | — | — |
| 2023 | -$32M | — | — |
| 2022 | -$31M | — | — |
| 2021 | -$28M | — | — |
| 2020 | -$28M | — | — |
| 2019 | -$30M | — | — |
| 2018 | -$21M | — | — |
| 2017 | -$11M | — | — |
| 2016 | -$9M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/STIM)